e-learning
resources
Milan 2017
Monday, 11.09.2017
New insights into pulmonary hypertension from recent trials
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia
S. Nathan (Falls Church, United States of America)
Source:
International Congress 2017 – New insights into pulmonary hypertension from recent trials
Session:
New insights into pulmonary hypertension from recent trials
Session type:
Oral Presentation
Number:
1985
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Nathan (Falls Church, United States of America). RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia. 1985
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis
Source: Eur Respir J 2012; 40: 93-100
Year: 2012
Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia
Source: Eur Respir J, 52 (1) 1800545; 10.1183/13993003.00545-2018
Year: 2018
Sildenafil for treatment of associated pulmonary hypertension in patients with severe COVID-19 pneumonia.
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
Cyclosporine A in the treatment of idiopathic pulmonary fibrosis/usual interstitial pneumonia
Source: Eur Respir J 2002; 20: Suppl. 38, 62s
Year: 2002
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study
Source: Annual Congress 2013 –Pulmonary circulation: treatment
Year: 2013
The classification, natural history and radiological/histological appearance of idiopathic pulmonary fibrosis and the other idiopathic interstitial pneumonias
Source: Eur Respir Rev 2008; 17: 108-115
Year: 2008
Pulmonary hypertension in idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis
Year: 2010
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Source: Eur Respir Mon 2012; 57: 148-160
Year: 2012
Diagnosis of pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 335s
Year: 2005
Idiopathic pulmonary haemosiderosis revisited
Source: Eur Respir J 2004; 24: 162-169
Year: 2004
Pulmonary hypertension is common in end-stage sarcoidosis
Source: Annual Congress 2005 - Progresses in granolomatous lung disease
Year: 2005
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome
Source: Eur Respir J 2010; 35: 105-111
Year: 2010
Vulnerability of fatal infection under steroid treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2002; 20: Suppl. 38, 354s
Year: 2002
Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF treatment II
Year: 2016
Interstitial lung diseases in childhood
Source: ISSN=1025-448x, ISBN=1-904097-22-7, page=213
Year: 2002
Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
Source: Eur Respir J 2005; 25: 528-533
Year: 2005
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Non-pulmonary comorbidities in idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction
Source: Eur Respir J 2015; 46: 1370-1377
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept